Regulation of cardiac hypertrophy by intracellular signalling pathways - Nature Reviews Molecular Cell Biology
- ️Molkentin, Jeffery D.
- ️Tue Aug 01 2006
Kannel, W. B. Vital epidemiologic clues in heart failure. J. Clin. Epidemiol. 53, 229–235 (2000).
Hobbs, R. E. Guidelines for the diagnosis and management of heart failure. Am. J. Ther. 11, 467–472 (2004).
Levy, D. et al. Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. 347, 1397–1402 (2002).
Zannad, F. et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J. Am. Coll. Cardiol. 33, 734–742 (1999).
Haldeman, G. A., Croft, J. B., Giles, W. H. & Rashidee, A. Hospitalization of patients with heart failure: national hospital discharge survey, 1985 to 1995. Am. Heart J. 137, 352–360 (1999).
Malek, M. Health economics of heart failure. Heart 82 (Suppl. 4), IV11–IV13 (1999).
Klein, L. et al. Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. Am. J. Cardiol. 91, 18F–40F (2003).
Lips, D. J., deWindt, L. J., van Kraaij, D. J. & Doevendans, P. A. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur. Heart J. 24, 883–896 (2003).
Berenji, K., Drazner, M. H., Rothermel, B. A. & Hill, J. A. Does load-induced ventricular hypertrophy progress to systolic heart failure? Am. J. Physiol. Heart Circ. Physiol. 289, H8–H16 (2005).
Haider, A. W., Larson, M. G., Benjamin, E. J. & Levy, D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J. Am. Coll. Cardiol. 32, 1454–1459 (1998).
Backs, J. & Olson, E. N. Control of cardiac growth by histone acetylation/deacetylation. Circ. Res. 98, 15–24 (2006).
Dorn, G. W. 2nd & Force, T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 115, 527–537 (2005).
Olson, E. N. & Schneider, M. D. Sizing up the heart: development redux in disease. Genes Dev. 17, 1937–1956 (2003).
Rockman, H. A., Koch, W. J. & Lefkowitz, R. J. Seven-transmembrane-spanning receptors and heart function. Nature 415, 206–212 (2002).
Wilkins, B. J. & Molkentin, J. D. Calcium–calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 322, 1178–1191 (2004).
Wu, X. et al. Local InsP(3)-dependent perinuclear Ca signaling in cardiac myocyte excitation-transcription coupling. J. Clin. Invest. 116, 675–682 (2006). A landmark study showing that a compartment-specific pool of Ca2+ near the nuclear envelope regulates CaMK activity and HDAC nuclear-cytoplasmic shuttling through Ins(1,4,5)P 3 -receptor-regulated Ca2+ release.
Clerk, A. & Sugden, P. H. Activation of protein kinase cascades in the heart by hypertrophic G protein-coupled receptor agonists. Am. J. Cardiol. 83, 64H–69H (1999).
Adams, J. W. et al. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc. Natl Acad. Sci. USA 95, 10140–10145 (1998).
D'Angelo, D. D. et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc. Natl Acad. Sci. USA 94, 8121–8126 (1997). Shows that simple overexpression of the G αq -subunit of the heterotrimeric G protein was sufficient to drive pathological cardiac hypertrophy in the mouse.
Fan, G. et al. A transgenic mouse model of heart failure using inducible Gαq. J. Biol. Chem. 280, 40337–40346 (2005).
Mende, U. et al. Transient cardiac expression of constitutively active Gαq leads to hypertrophy and dilated cardiomyopathy by calcineurin-dependent and independent pathways. Proc. Natl Acad. Sci. USA 95, 13893–13898 (1998).
Akhter, S. A. et al. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280, 574–577 (1998). First study showing that G αq/α11 protein function is necessary for mediating cardiac hypertrophy in an animal model of pressure-overload-induced hypertrophy.
Esposito, G. et al. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85–92 (2002). Shows that inhibition of pressure-overload hypertrophy through two separate means in genetically altered mice did not lead to decompensation and heart failure, indicating that hypertrophy might not be necessary for cardiac compensation.
Wettschureck, N. et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Gαq/Gα11 in cardiomyocytes. Nature Med. 7, 1236–1240 (2001). Heart specific and combined disruption of the genes that encode G αq and G α11 inhibited the cardiac hypertrophic response following pressure-overload stimulation.
Rogers, J. H. et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104, 567–576 (1999).
Asakura, M. et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nature Med. 8, 35–40 (2002).
Gschwind, A., Zwick, E., Prenzel, N., Leserer, M. & Ullrich, A. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene 20, 1594–1600 (2001).
Garratt, A. N., Ozcelik, C. & Birchmeier, C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc. Med. 13, 80–86 (2003).
Crone, S. A. et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med. 8, 459–465 (2002).
Ozcelik, C. et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 8880–8885 (2002).
Ross, R. S. & Borg, T. K. Integrins and the myocardium. Circ. Res. 88, 1112–1119 (2001).
Brancaccio, M. et al. Melusin, a muscle-specific integrin β1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nature Med. 9, 68–75 (2003). Melusin is required for the adaptive hypertrophic response to biomechanical stimuli but not biochemical stimuli (such as G-protein-coupled receptor agonists).
Knoll, R. et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111, 943–955 (2002).
Heineke, J. et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM protein-calcineurin signaling at the sarcomeric Z-disc. Proc. Natl Acad. Sci. USA 102, 1655–60 (2005).
Arber, S. et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88, 393–403 (1997).
Shai, S. Y. et al. Cardiac myocyte-specific excision of the β1 integrin gene results in myocardial fibrosis and cardiac failure. Circ. Res. 90, 458–464 (2002).
Peng, X. et al. Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice. J. Clin. Invest. 116, 217–227 (2006).
Zou, Y. et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nature Cell Biol. 6, 499–506 (2004).
Garrington, T. P. & Johnson, G. L. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr. Opin. Cell Biol. 11, 211–218 (1999).
Sugden, P. H. & Clerk, A. 'Stress-responsive' mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83, 345–352 (1998).
Yamamoto, S. et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest. 111, 1463–1474 (2003).
Bueno, O. F. et al. The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341–6350 (2000). First description that MEK1–ERK1/2 signalling could induce and maintain cardiac hypertrophy in the mouse, and that the hypertrophy that was mediated by this pathway was not overtly pathologic.
Sanna, B., Bueno, O. F., Dai, Y. S., Wilkins, B. J. & Molkentin, J. D. Direct and indirect interactions between calcineurin–NFAT and MEK1–extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth. Mol. Cell. Biol. 25, 865–878 (2005).
Hunter, J. J., Tanaka, N., Rockman, H. A., Ross, J. Jr. & Chien, K. R. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J. Biol. Chem. 270, 23173–23178 (1995).
Molkentin, J. D. & Dorn, G. W. 2nd. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391–426 (2001).
Harris, I. S. et al. Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation 110, 718–723 (2004).
Baccarini, M. Second nature: biological functions of the Raf-1 'kinase'. FEBS Lett. 579, 3271–3277 (2005).
Hindley, A. & Kolch, W. Extracellular signal regulated kinase (ERK)/mitogen activated protein kinase (MAPK)-independent functions of Raf kinases. J. Cell Sci. 115, 1575–1581 (2002).
Nicol, R. L. et al. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20, 2757–2767 (2001). Shows that the MEK5–ERK5 pathway controls one unique aspect of cardiac growth in vivo by addition of sarcomeres in series in transgenic mice.
Liao, P. et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc. Natl Acad. Sci. USA 98, 12283–12288 (2001). Shows that p38 activation in the mouse heart is cardiomyopathic and induces dilation and failure, but not hypertrophy.
Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nature Med. 6, 556–563 (2000).
Petrich, B. G. et al. c-Jun N-terminal kinase activation mediates downregulation of connexin43 in cardiomyocytes. Circ. Res. 91, 640–647 (2002).
Petrich, B. G., Molkentin, J. D. & Wang, Y. Temporal activation of c-Jun N-terminal kinase in adult transgenic heart via cre-loxP-mediated DNA recombination. FASEB J. 17, 749–751 (2003).
Molkentin, J. D. Calcineurin–NFAT signaling regulates the cardiac hypertrophic response in coordination with the MAPKs. Cardiovasc. Res. 63, 467–475 (2004).
Liang, Q. et al. c-Jun N-terminal kinases (JNK) antagonize cardiac growth through cross-talk with calcineurin–NFAT signaling. EMBO J. 22, 5079–5089 (2003). Inhibition of JNK1/JNK2 signalling in either gene-targeted mice or transgenic mice that express dominant-negative mutants induces cardiac hypertrophy by augmenting calcineurin–NFAT signalling, similar to the inhibition of p38 signalling.
Tachibana, H. et al. JNK1 is required to preserve cardiac function in the early response to pressure overload. Biochem. Biophys. Res. Commun. 343, 1060–1066 (2006).
Kaiser, R. A. et al. Genetic inhibition or activation of JNK1/2 protects the myocardium from ischemia-reperfusion-induced cell death in vivo. J. Biol. Chem. 280, 32602–32608 (2005).
Braz, J. C. et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin–NFAT signaling. J. Clin. Invest. 111, 1475–1486 (2003). Inhibition of p38 signalling in transgenic mice that express dominant-negative mutants induces and enhances cardiac hypertrophy by augmenting calcineurin–NFAT signalling, similar to the inhibition of JNK signalling.
Zhang, S. et al. The role of the Grb2–p38 MAPK signaling pathway in cardiac hypertrophy and fibrosis. J. Clin. Invest. 111, 833–841 (2003).
Nishida, K. et al. p38α mitogen-activated protein kinase plays a critical role in cardiomyocyte survival but not in cardiac hypertrophic growth in response to pressure overload. Mol. Cell. Biol. 24, 10611–10620 (2004).
Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998). Myocardial overexpression of activated calcineurin results in pronounced cardiac hypertrophy, which results in heart failure.
Wilkins, B. J. et al. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin-mediated cardiac hypertrophic growth. Mol. Cell. Biol. 22, 7603–7613 (2002).
Frey, N. et al. Mice lacking calsarcin-1 are sensitized to calcineurin signaling and show accelerated cardiomyopathy in response to pathological biomechanical stress. Nature Med. 10, 1336–1343 (2004).
Frey, N., Richardson, J. A. & Olson, E. N. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc. Natl Acad. Sci. USA 97, 14632–14637 (2000).
Li, H. H. et al. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J. Clin. Invest. 114, 1058–1071 (2004).
Antos, C. L. et al. Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 99, 907–912 (2002).
Bueno, O. F., van Rooij, E., Molkentin, J. D., Doevendans, P. A. & De Windt, L. J. Calcineurin and hypertrophic heart disease: novel insights and remaining questions. Cardiovasc. Res. 53, 806–821 (2002).
De Windt, L. J. et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 98, 3322–3327 (2001).
Hill, J. A. et al. Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function. J. Biol. Chem. 277, 10251–10255 (2002).
Rothermel, B. A. et al. Myocyte-enriched calcineurin-interacting protein, MCIP1, inhibits cardiac hypertrophy in vivo. Proc. Natl Acad. Sci. USA 98, 3328–3333 (2001).
Sanna, B. et al. Modulatory calcineurin-interacting proteins 1 and 2 function as calcineurin facilitators in vivo. Proc. Natl Acad. Sci. USA 103, 7327–7332 (2006).
Vega, R. B. et al. Dual roles of modulatory calcineurin-interacting protein 1 in cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100, 669–674 (2003).
Zou, Y. et al. Calcineurin plays a critical role in the development of pressure overload-induced cardiac hypertrophy. Circulation 104, 97–101 (2001).
Bueno, O. F. et al. Impaired cardiac hypertrophic response in calcineurin Aβ-deficient mice. Proc. Natl Acad. Sci. USA 99, 4586–4591 (2002). Mice that lack calcineurin Aβ have an impaired hypertrophic response after transverse aortic constriction, isoproterenol and angiotensin II infusion.
Wilkins, B. J. et al. Calcineurin–NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110–118 (2004).
Bueno, O. F. et al. Calcineurin Aβ gene targeting predisposes the myocardium to acute ischemia-induced apoptosis and dysfunction. Circ. Res. 94, 91–99 (2004).
Oudit, G. Y. et al. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol. 37, 449–471 (2004).
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
Shioi, T. et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537–2548 (2000). Overexpression of activated PI3Kα leads to a physiological form of hypertrophy without functional impairment of cardiac function up to one year.
McMullen, J. R. et al. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100, 12355–12360 (2003).
Luo, J. et al. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol. 25, 9491–9502 (2005).
Crackower, M. A. et al. Regulation of myocardial contractility and cell size by distinct PI3K–PTEN signaling pathways. Cell 110, 737–749 (2002).
Patrucco, E. et al. PI3Kγ modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and-independent effects. Cell 118, 375–387 (2004). References 82 and 83 show differential effects of PI3Kα and PI3Kγ. PI3Kα mediates physiological hypertrophy, whereas PI3Kγ contributes to hypertrophy in response to pathological stimuli and also reduces cardiac contractility.
Chen, W. S. et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15, 2203–2208 (2001).
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F. & Birnbaum, M. J. Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276, 38349–38352 (2001).
Cho, H. et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728–1731 (2001).
DeBosch, B. et al. Akt1 is required for physiological cardiac growth. Circulation 113, 2097–2104 (2006).
Condorelli, G. et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl Acad. Sci. USA 99, 12333–12338 (2002).
Matsui, T. et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277, 22896–22901 (2002).
Shioi, T. et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol. 22, 2799–2809 (2002).
Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108–2118 (2005). Shows that short-term overexpression of activated AKT in the adult myocardium induces compensated hypertrophy with coordinated myocyte and capillary growth; capillary growth was shown to be essential for myocardial growth and functional compensation.
Shiraishi, I. et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res. 94, 884–891 (2004).
Rota, M. et al. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res. 97, 1332–1341 (2005).
Proud, C. G. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc. Res. 63, 403–413 (2004).
Sanbe, A. et al. Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ. Res. 92, 609–616 (2003).
McMullen, J. R. et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 109, 3050–3055 (2004).
Shioi, T. et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664–1670 (2003).
McMullen, J. R. et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 24, 6231–6240 (2004).
Pende, M. et al. S6K1−/−/S6K2−/− mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24, 3112–3124 (2004).
Montagne, J. et al. Drosophila S6 kinase: a regulator of cell size. Science 285, 2126–2129 (1999).
Shima, H. et al. Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17, 6649–6659 (1998).
Vega, R. B. et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 24, 8374–8385 (2004).
Molkentin, J. D. Dichotomy of Ca in the heart: contraction versus intracellular signaling. J. Clin. Invest. 116, 623–626 (2006).
Miska, E. A. et al. HDAC4 deacetylase associates with and represses the MEF2 transcription factor. EMBO J. 18, 5099–5107 (1999).
Lu, J., McKinsey, T. A., Nicol, R. L. & Olson, E. N. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc. Natl Acad. Sci. USA 97, 4070–4075 (2000).
Sparrow, D. B. et al. MEF-2 function is modified by a novel co-repressor, MITR. EMBO J. 18, 5085–5098 (1999).
Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488 (2002). Shows, with reference 108, that mutant mice that lack either HDAC5 or HDAC9 (both class II HDACs) have an augmented cardiac growth response to pathological stimuli (aortic constriction and calcineurin overexpression) and advanced age.
Chang, S. et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24, 8467–8476 (2004).
Kee, H. J. et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113, 51–59 (2006). Shows that pharmacological inhibition of HDACs reduces cardiac hypertrophy in mice and rats that is induced by various pathological stimuli. HDAC inhibition also blunted pre-existing myocardial hypertrophy and reduced mortality after transverse aortic constriction.
Kong, Y. et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579–2588 (2006).
Mei, S., Ho, A. D. & Mahlknecht, U. Role of histone deacetylase inhibitors in the treatment of cancer (Review). Int. J. Oncol. 25, 1509–1519 (2004).
Sano, M. & Schneider, M. D. Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades. Circ. Res. 95, 867–876 (2004).
Sano, M. et al. Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy. Nature Med. 8, 1310–1317 (2002). Novel paradigm for the regulation of heart growth through the activation of CDK7 and CDK9 to facilitate RNA polymerase II transcription elongation, and the augmentation of hypertrophic gene expression.
Passier, R. et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J. Clin. Invest. 105, 1395–1406 (2000).
Zhang, R. et al. Calmodulin kinase II inhibition protects against structural heart disease. Nature Med. 11, 409–417 (2005).
Zhang, T. et al. The δC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92, 912–919 (2003).
Haq, S. et al. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nature Med. 9, 944–951 (2003).
Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Med. 11, 214–222 (2005). Blockade of catabolism of cGMP with the oral phosphodiesterase-5A (PDE5A) inhibitor sildenafil (Viagra) suppresses cardiac hypertrophy and improves heart function in mice that were exposed to aortic banding.
Wollert, K. C. et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39, 87–92 (2002).
Fiedler, B. et al. Inhibition of calcineurin–NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc. Natl Acad. Sci. USA 99, 11363–11368 (2002).
Deschamps, A. M. & Spinale, F. G. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc. Res. 69, 666–676 (2006).
Kang, P. M. & Izumo, S. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol. Med. 9, 177–182 (2003).
Dickhuth, H. H., Rocker, K., Mayer, F., Konig, D. & Korsten-Reck, U. Endurance training and cardial adaptation (athlete's heart). Herz 29, 373–380 (2004).
Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074–1080 (2001).
de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S. & van Kuilenburg, A. B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370, 737–749 (2003).
Verdin, E., Dequiedt, F. & Kasler, H. G. Class II histone deacetylases: versatile regulators. Trends Genet. 19, 286–293 (2003).
Molkentin, J. D. The zinc finger-containing transcription factors GATA-4, -5, and-6. Ubiquitously expressed regulators of tissue-specific gene expression. J. Biol. Chem. 275, 38949–38952 (2000).
Peterkin, T., Gibson, A., Loose, M. & Patient, R. The roles of GATA-4, -5 and-6 in vertebrate heart development. Semin. Cell Dev. Biol. 16, 83–94 (2005).
Akazawa, H. & Komuro, I. Roles of cardiac transcription factors in cardiac hypertrophy. Circ. Res. 92, 1079–1088 (2003).
Liang, Q. & Molkentin, J. D. Divergent signaling pathways converge on GATA4 to regulate cardiac hypertrophic gene expression. J. Mol. Cell. Cardiol. 34, 611–616 (2002).
Liang, Q. et al. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J. Biol. Chem. 276, 30245–30253 (2001).
Oka, T. et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 98, 837–845 (2006). Cardiac-specific deletion of Gata4 results in a progressive deterioration in cardiac function and dilation in adulthood. Also shows that GATA4 is important for the preservation of cardiac function in response to pressure overload of the heart.
Karin, M. The beginning of the end: IκB kinase (IKK) and NF-κB activation. J. Biol. Chem. 274, 27339–27342 (1999).
Kawano, S. et al. Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc. Res. 67, 689–698 (2005).
Freund, C. et al. Requirement of nuclear factor-κB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 111, 2319–2325 (2005).
Li, Y. et al. NF-κB activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol. Heart Circ. Physiol. 287, H1712–H1720 (2004).
Czubryt, M. P. & Olson, E. N. Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog. Horm. Res. 59, 105–124 (2004).
Han, J. & Molkentin, J. D. Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology. Trends Cardiovasc. Med. 10, 19–22 (2000).
Xu, J. et al. Myocyte enhancer factors 2A and 2C induce dilated cardiomyopathy in transgenic mice. J. Biol. Chem. 281, 9152–9162 (2006).
Zhang, X. et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am. J. Physiol. Heart Circ. Physiol. 280, H1782–H1792 (2001).
Parlakian, A. et al. Temporally controlled onset of dilated cardiomyopathy through disruption of the SRF gene in adult heart. Circulation 112, 2930–2939 (2005).
Buitrago, M. et al. The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nature Med. 11, 837–844 (2005).
Song, K. et al. The transcriptional coactivator CAMTA2 stimulates cardiac growth by opposing class II histone deacetylases. Cell 124, 435–466 (2006).